Pharmacokinetics and tissue elimination of tulathromycin following subcutaneous administration in meat goats

American Journal of Veterinary Research

Volumn 73, Issue 10, 2012, Pages 1634-1640

  Romanet, Jessica ^a   Smith, Geof W ^a   Leavens, Teresa L ^a   Baynes, Ronald E ^a   Wetzlich, Scott E ^b   Riviere, Jim E ^a   Tell, Lisa A ^b  

^a NORTH CAROLINA STATE UNIVERSITY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TULATHROMYCIN;

ADIPOSE TISSUE; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; DRUG TISSUE LEVEL; FEMALE; GOAT; KIDNEY PARENCHYMA; LUNG PARENCHYMA; MALE; MAXIMUM PLASMA CONCENTRATION; MEAT; MUSCLE TISSUE; NONHUMAN; TANDEM MASS SPECTROMETRY; TIME TO MAXIMUM PLASMA CONCENTRATION; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY;

ANIMALS; ANTI-BACTERIAL AGENTS; DISACCHARIDES; FEMALE; GOATS; HETEROCYCLIC COMPOUNDS; INJECTIONS, SUBCUTANEOUS; MALE; TANDEM MASS SPECTROMETRY; TIME FACTORS; TISSUE DISTRIBUTION;

ANIMALIA; BOS; CAPRA HIRCUS;

EID: 84867036569     PISSN: 00029645     EISSN: None     Source Type: Journal    
DOI: 10.2460/ajvr.73.10.1634     Document Type: Article

References (19)

1. Christodoulopoulos G, Warnick LD, Papaioannou N, et al. Tilmicosin administration to young lambs with respiratory infection: safety and efficacy considerations. J Vet Pharmacol Ther 2002;25:393-397.
2. Evans N. Tulathromycin: an overview of a new triamilide antibiotic for livestock respiratory disease. Vet Ther 2005;6:83-95.
3. Nowakowski MA, Inskeep PB, Risk JE, et al. Pharmacokinetics and lung tissue concentrations of tulathromycin, a new triamilide antibiotic, in cattle. Vet Ther 2004;5:60-74.
4. Galer D, Hessong S, Beato B, et al. An analytical method for the analysis of tulathromycin, an equilibrating triamilide, in bovine and porcine plasma and lung. J Agric Food Chem 2004;52:2179-2191.
5. Washburn KE, Bissett W, Fajt V, et al. The safety of tulathromycin administration in goats. J Vet Pharmacol Ther 2007;30:267-270.
6. Washburn KE, Bissett WT, Fajt VR, et al. Comparison of three treatment regimens for sheep and goats with caseous lymphadenitis. J Am Vet Med Assoc 2009;234:1162-1166.
7. Clothier KA, Jordan DM, Loynachan AT, et al. Safety evaluation of tulathromycin use in the caprine species: tulathromycin toxicity assessment in goats. J Vet Pharmacol Ther 2010;33:499-502.
8. Clothier KA, Leavens T, Griffith RW, et al. Pharmacokinetics of tulathromycin after single and multiple subcutaneous injections in domestic goats (Carpra aegagrus hircus). J Vet Pharmacol Ther 2011;34:448-454.
9. Young G, Smith GW, Leavens TL, et al. Pharmacokinetics of tulathromycin following subcutaneous administration in meat goats. Res Vet Sci 2011;90:477-479.
10. Benchaoui HA, Nowakowski M, Sherington J, et al. Pharmacokinetics and lung tissue concentrations of tulathromycin in swine. J Vet Pharmacol Ther 2004;27:203-210.
11. Boner PL, Gottschall DW. Determination and confirmation of tulathromycin residues in bovine liver and porcine kidney via their common hydrolytic fragment using high-performance liquid chromatography/tandem mass spectrometry. J AOAC Int 2011;94:436-445.
12. Clothier KA, Leavens T, Griffith RW, et al. Tulathromycin assay validation and tissue residues after single and multiple subcutaneous injections in domestic goats (Capra aegagrus hircus). J Vet Pharmacol Ther 2012;35:113-120.
13. US FDA. Guidance for industry: general principles for evaluating the safety of compounds used in food producing animals. 2006. Available at: www.fda.gov/downloads/AnimalVeterinary/ GuidanceComplianceEnforcement/GuidanceforIndustry/ UCM052180.pdf. Accessed Oct 6, 2011.
14. USDA. 2007 census of agriculture, geographic area series. Summary and state data. Vol 1. 2009;430-433. Available at: www. agcensus.usda.gov/Publications/2007/Full_Report/usv1.pdf. Accessed Oct 6, 2011.
15. FDA. AMDUCA. 1994;21 CFR 530:1-41.
16. Godinho KS. Susceptibility testing of tulathromycin: interpretative breakpoints and susceptibility of field isolates. Vet Microbiol 2008;129:426-432.
17. Kilgore WR, Spensley MS, Sun F, et al. Therapeutic efficacy of tulathromycin, a novel triamilide antimicrobial, against bovine respiratory disease in feeder calves. Vet Ther 2005;6:143-153.
18. Clothier KA, Kinyon JM, Griffith RW. Antimicrobial susceptibility patterns and sensitivity to tulathromycin in goat respiratory bacterial isolates. Vet Microbiol 2012;156:178-182.
19. FDA. Freedom of Information summary for tulathromycin. Original new animal drug application, NADA 141-244, approved May 24, 2005. Available at: www.fda.gov/downloads/ AnimalVeterinary/Products/ApprovedAnimalDrugProducts/ FOIADrugSummaries/ucm118061.pdf. Accessed Jun 15, 2012.